Center for Scientific Review; Notice of Closed Meeting, 89481 [2016-29603]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 238 / Monday, December 12, 2016 / Notices
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered to this
population; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered to this population, or the
program planner or qualified person
reasonably could have believed the
recipient was in this population.
XI. Geographic Area
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(D)
Program (CICP) to provide benefits to
certain individuals or estates of
individuals who sustain a covered
serious physical injury as the direct
result of the administration or use of the
Covered Countermeasures, and benefits
to certain survivors of individuals who
die as a direct result of the
administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical and scientific evidence in order
for the individual to be considered for
compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available by telephone at 855–266–2427
(toll-free) or https://www.hrsa.gov/cicp/.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call)
Contact Person: Ganesan Ramesh, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Dr., Room 2182, MSC
7818, Bethesda, MD 20892, ganesan.ramesh@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
XV. Amendments
BILLING CODE 4140–01–P
42 U.S.C. 247d–6d(b)(4)
Any amendments to this Declaration
will be published in the Federal
Register.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Liability immunity is afforded for the
administration or use of a Covered
Countermeasure without geographic
limitation.
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered in any
designated geographic area; liability
immunity is afforded to program
planners and qualified persons when
the countermeasure is used by or
administered in any designated
geographic area, or the program planner
or qualified person reasonably could
have believed the recipient was in that
geographic area.
Dated: December 2, 2016.
Sylvia M. Burwell,
Secretary, Department of Health and Human
Services.
XII. Effective Time Period
[FR Doc. 2016–29609 Filed 12–9–16; 8:45 am]
42 U.S.C. 247d–6d(b)(2)(B)
BILLING CODE 4150–28–P
Liability immunity for Covered
Countermeasures began on February 27,
2015, and extends through February 26,
2019.
XIII. Additional Time Period of
Coverage
Authority: 42 U.S.C. 247d–6d.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK3G9T082PROD with NOTICES
42 U.S.C. 247d–6d(b)(3)(B) and (C)
Center for Scientific Review; Notice of
Closed Meeting
I have determined that an additional
12 months of liability protection is
reasonable to allow for the
manufacturer(s) to arrange for
disposition of the Covered
Countermeasure, including return of the
Covered Countermeasures to the
manufacturer, and for Covered Persons
to take such other actions as are
appropriate to limit the administration
or use of the Covered Countermeasures.
Covered Countermeasures obtained
for the SNS during the effective period
of this Declaration are covered through
the date of administration or use
pursuant to a distribution or release
from the SNS.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
XIV. Countermeasures Injury
Compensation Program
42 U.S.C 247d–6e
The PREP Act authorizes the
Countermeasures Injury Compensation
VerDate Sep<11>2014
20:00 Dec 09, 2016
Jkt 241001
89481
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neurogastroenterology.
Date: December 14, 2016.
Time: 9:00 a.m. to 10:00 a.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Dated: December 6, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–29603 Filed 12–9–16; 8:45 am]
National Institutes of Health
National Eye Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Eye Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Eye Council.
Date: January 19, 2017.
Open: 8:30 a.m. to 1:00 p.m.
Agenda: Following opening remarks by the
Director, NEI, there will be presentations by
the staff of the Institute and discussions
concerning Institute programs.
Place: Terrace Level Conference Rooms,
5635 Fishers Lane, Rockville, MD 20852.
E:\FR\FM\12DEN1.SGM
12DEN1
]]>Agencies
[Federal Register Volume 81, Number 238 (Monday, December 12, 2016)]
[Notices]
[Page 89481]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-29603]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Neurogastroenterology.
Date: December 14, 2016.
Time: 9:00 a.m. to 10:00 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call)
Contact Person: Ganesan Ramesh, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge Dr., Room 2182, MSC
7818, Bethesda, MD 20892, ganesan.ramesh@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: December 6, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-29603 Filed 12-9-16; 8:45 am]
BILLING CODE 4140-01-P
